ERASCA DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ERAS

A securities class action lawsuit has been filed against Erasca, Inc. and its executives for allegedly making false and misleading statements about its lead oncology drug candidate ERAS-0015. The company is accused of improperly comparing its drug to a competitor's candidate and failing to disclose patent and trade secret disputes. Investors who purchased Erasca stock between January 14, 2025 and April 26, 2026 may be eligible for compensation. The deadline to serve as lead plaintiff is August 10, 2026.